[1]OBERG K.Neuroendocrine tumours(NETs):historical overview and epidemiology[J].Tumori,2010,96(5):797-801.
|
[2]LIANG HJ.Diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J].Chin J Digest Surg,2014,13(10):756-759.(in Chinese)梁后杰.胃肠胰神经内分泌肿瘤的诊断与治疗[J].中华消化外科杂志,2014,13(10):756-759.
|
[3]KOMMINOTH P,ARNOLD R,CAPELLA C,et al.Neuroendocrine neoplasms of the gallbladder and extrahepatic bile ducts[M].WHO Classification of Tumours of the Digestive System,2010:274-276.
|
[4]ALBORES-SAAVEDRA J,NADJI M,HENSON DE,et al.Intestinal metaplasia of the gallbladder:a morphologic and immunocytochemical study[J].Hum Pathol,1986,17(6):614-620.
|
[5]KULKE MH.Neuroendocrine tumours:clinical presentation and management of localized disease[J].Cancer Treat Rev,2003,29(5):363-370.
|
[6]OBERG K,ERIKSSON B.Nuclearmedicine in the detection,staging and treatment of gastrointestinal carcinoid tumours[J].Best Pract Res Clin Endocrinol Metab,2005,19(2):265-276.
|
[7]VINIK AI,WOLTERJING EA,WARNER RR,et al.NANETS consensus guidelines for the diagnosis of Neuroendocrine tumour[J].Pancreas,2010,39(6):713-734.
|
[8]LAMBERTS SW,HOFLAND LJ,NOBELS FR.Neuroendocrine tumor markers[J].Front Neuroendocrinol,2001,22(4):309-339.
|
[9]STRIDSBERG M,ERIKSSON B,OBERG K,et al.A comparison between three commercial kits for chromogranin a measurements[J].J Endocrinol,2003,177(2):337-341.
|
[10]BAUDIN E.Gastroenteropancreatic endocrine tumors:clinical characterization before therapy[J].Nat Clin Pract Endocrinol Metab,2007,3(3):228-239.
|
[11]ZHU XZ.Evolution of the digestive system tumor diagnostic terminology and its clinical significance[J].Chin J Gastrointest Surg,2011,14(1):20-22.(in Chinese)朱雄增.消化系统肿瘤一些诊断术语的演变及其临床意义[J].中华胃肠外科杂志,2011,14(1):20-22.
|
[12]RINDI G,KLPPEL G,ALHMAN H,et al.TNM staging of foregut(neuro)endocrine tumors:a consensus proposal including a grading system[J].Virchows Arch,2006,449(4):395-401.
|
[13]ZHOU X,ZANG H,LIU HL.An excerpt of intrahepatic cholangiocar cioma:expert consensus statement[J].J Clin Hepatol,2015,31(10):1584-1587.(in Chinese)周霞,臧红,刘鸿凌.《2014年美国肝胆胰学会共识声明:肝内胆管癌管理》摘译[J].临床肝胆病杂志,2015,31(10):1584-1587.
|
[14]RAYMOND E,DAHAN L,RAOUL JL,et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J].N Engl J Med,2011,364(6):501-513.
|
[15] YAO JC,SHAH MH,ITO T,et al.Everolimus for advanced pancreatic neuroendocrine tumors[J].N Engl J Med,2011,364(6):514-523.
|
[16]SALTZ L,KEMENY N,SCHWARTZ G,et al.A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors[J].Cancer,1994,74(3):958-961.
|
[17]BRUNS C,LEWIS I,BRINER U,et al.SOM230:a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor(SRIF)receptor binding and a unique antisecretory profile[J].Eur J Endocrinol,2002,146(5):707-716.
|